Literature DB >> 16953033

Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53.

Okto Dewantoro1, Rino A Gani, Nurul Akbar.   

Abstract

Infection of Hepatitis B Virus (HBV) is a risk factor of chronic active hepatitis (CAH), hepatic cirrhosis and hepatocellular carcinoma (HCC). Infection of HBV may develop to HCC without antecedent hepatic cirrhosis. Pathogenesis of HBV causing malignant changes has not been fully understood. HBx, a protein of HBV, is an activator of transcription process involved in hepatocarcinogenesis. Most of human cancer associated with mutation of p53, a Tumor Suppressor Genes, a protein serves as cellular protection for growth and cell division, which is one of predisposition factor of hepatocarcinoma. Some studies indicate the correlation between mutation / inactivation of p53 and HBV protein x (HBx) in hepatocarcinogenesis. In that process, HBx will suppress p53 function, which will lead to ineffective liver cell division and resulting in HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953033

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  19 in total

Review 1.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.

Authors:  Ningning Liu; Jinfang Zhang; Xiaohai Yang; Tong Jiao; Xin Zhao; Wenxia Li; Jianhua Zhu; Pu Yang; Jianping Jin; Jirun Peng; Zhiwei Li; Xin Ye
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 3.  Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.

Authors:  Ashraf Ali; Hany Abdel-Hafiz; Mohd Suhail; Amany Al-Mars; Mohammad Khalid Zakaria; Kaneez Fatima; Sultan Ahmad; Esam Azhar; Adeel Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

4.  Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.

Authors:  Xiaojie Xu; Zhongyi Fan; Lei Kang; Juqiang Han; Chengying Jiang; Xiaofei Zheng; Ziman Zhu; Huabo Jiao; Jing Lin; Kai Jiang; Lihua Ding; Hao Zhang; Long Cheng; Hanjiang Fu; Yi Song; Ying Jiang; Jiahong Liu; Rongfu Wang; Nan Du; Qinong Ye
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 5.  Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yinli Yang; Bingqing Zheng; Qiuju Han; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

Review 6.  Hepatitis B virus infection and intrahepatic cholangiocarcinoma.

Authors:  Hua-Bang Zhou; Jing-Yi Hu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 7.  Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin's lymphoma: a systematic review and a meta-analysis.

Authors:  Hai-zhen Yi; Jin-jing Chen; Hong Cen; Wei Yan; Xiao-hong Tan
Journal:  Med Oncol       Date:  2014-06-28       Impact factor: 3.064

8.  COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma.

Authors:  Xiao-Hong Liu; Jing Lin; Shu-Hui Zhang; Shun-Min Zhang; Mark-A Feitelson; Heng-Jun Gao; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

9.  Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma.

Authors:  Chia-Jui Yen; Yih-Jyh Lin; Chia-Sheng Yen; Hung-Wen Tsai; Ting-Fen Tsai; Kwang-Yu Chang; Wei-Chien Huang; Pin-Wen Lin; Chi-Wu Chiang; Ting-Tsung Chang
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells.

Authors:  Yun-Ju Chen; Pei-Hsuan Chien; Wen-Shu Chen; Yu-Fong Chien; Ya-Ying Hsu; Li-Yun Wang; Jhen-Yu Chen; Chih-Wen Lin; Tzung-Chi Huang; Yung-Luen Yu; Wei-Chien Huang
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-11       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.